AR031599A1 - Vacunas para el virus herpes equino tipo 1: virus que hospeda mutaciones dentro del gen inmediato precoz - Google Patents

Vacunas para el virus herpes equino tipo 1: virus que hospeda mutaciones dentro del gen inmediato precoz

Info

Publication number
AR031599A1
AR031599A1 ARP010103602A AR031599A1 AR 031599 A1 AR031599 A1 AR 031599A1 AR P010103602 A ARP010103602 A AR P010103602A AR 031599 A1 AR031599 A1 AR 031599A1
Authority
AR
Argentina
Prior art keywords
immediate
vhe
isolates
hev
gene
Prior art date
Application number
Other languages
English (en)
Original Assignee
Res Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Corp Technologies Inc filed Critical Res Corp Technologies Inc
Publication of AR031599A1 publication Critical patent/AR031599A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se refiere a los aislados del virus herpes equino tipo 1(VHE-1)mutante, y en particular a los aislados VHE-1 que transportan mutaciones en el gen inmediato-precoz (IP) del genoma viral. Un panel de aislado del VHE-1 mutante se ha descripto en la presente. Los aislados del VHE-1 preferidos son aquellos que son de replicacion-competente y no patogénica. Los aislados del VHE-1 mutante de la presente invencion son utiles para formular composiciones de vacuna para impedir y tratar las infecciones por el VHE-1 en los equinos. Además la presente proporciona los métodos para determinar la patogenicidad de un VHE-1 presente en un equino que ha sido previamente inmunizado con un aislado de VHE-1 no patogénico.
ARP010103602 2000-07-27 2001-07-27 Vacunas para el virus herpes equino tipo 1: virus que hospeda mutaciones dentro del gen inmediato precoz AR031599A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62674800A 2000-07-27 2000-07-27

Publications (1)

Publication Number Publication Date
AR031599A1 true AR031599A1 (es) 2003-09-24

Family

ID=24511676

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103602 AR031599A1 (es) 2000-07-27 2001-07-27 Vacunas para el virus herpes equino tipo 1: virus que hospeda mutaciones dentro del gen inmediato precoz

Country Status (9)

Country Link
EP (1) EP1317481A2 (es)
JP (1) JP2004512826A (es)
AR (1) AR031599A1 (es)
AU (1) AU2001282997A1 (es)
CA (1) CA2417340A1 (es)
DE (1) DE01961753T1 (es)
MX (1) MXPA03000823A (es)
NZ (1) NZ523772A (es)
WO (1) WO2002009750A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1129722A1 (en) 2000-02-17 2001-09-05 Boehringer Ingelheim Vetmedica Gmbh gM-negative EHV-mutants
AR040601A1 (es) 2002-07-19 2005-04-13 Boehringer Ingelheim Vetmed Mutantes ehv negativos de gm sin elementos heterologos
AU2003251356A1 (en) * 2002-07-26 2004-02-16 Animal Health Trust Viral marker
AU2013235423B2 (en) * 2012-03-20 2017-03-30 Boehringer Ingelheim Animal Health USA Inc. Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein C and uses thereof
CN108315487B (zh) * 2018-04-16 2021-06-22 福建省农业科学院生物技术研究所 一种检测鳗鲡疱疹病毒的引物组、试剂盒及其应用
CN110885794A (zh) * 2019-10-30 2020-03-17 新疆农业大学 一种马疱疹病毒1型及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292653A (en) * 1989-09-27 1994-03-08 Novagene, Inc. Equine herpesvirus 1 tk mutants
EP0668355B1 (en) * 1993-12-20 1999-04-07 Akzo Nobel N.V. Vaccine for the protection of horses against equine herpesvirus infection

Also Published As

Publication number Publication date
DE01961753T1 (de) 2004-03-11
JP2004512826A (ja) 2004-04-30
CA2417340A1 (en) 2002-02-07
EP1317481A2 (en) 2003-06-11
AU2001282997A1 (en) 2002-02-13
WO2002009750A2 (en) 2002-02-07
MXPA03000823A (es) 2003-09-10
WO2002009750A3 (en) 2003-03-27
NZ523772A (en) 2004-06-25

Similar Documents

Publication Publication Date Title
ES2140418T3 (es) Flavivirus quimericos y/o flavivirus de crecimiento restringido.
MX342639B (es) Virus de la influenza recombinantes de alta titulacion para vacunas y terapia genica.
PL398576A1 (pl) Preparaty szczepionek, preparaty farmaceutyczne, atenuowany wirus grypy, sposoby szczepienia, sposoby zapobiegania chorobie zakaznej, sposoby leczenia lub profilaktyki nowotworów, kompozycje szczepionek i kompozycje farmaceutyczne
NO20025171L (no) DNA-transfeksjonssystem for fremstilling av smittsom influensavirus
NL300364I1 (nl) Recombinante influenzavirussen voor vaccins en gentherapie
CR8935A (es) Inhibidores de la arn polimerasa dependiente del arn del virus de la hepatitis c y composiciones
ES2059370T3 (es) Un virus herpes simplex recombinante, vacunas y metodos.
AR038596A1 (es) Sistemas de expresion de virus parainfluenza recombinantes y vacunas que comprenden antigenos heterologos derivados de metapneumovirus
HUP9903822A2 (hu) Polinukleotid-vakcinakészítmény sertések szaporodásbiológiai és légzőszervi kórképei ellen
PE20030285A1 (es) Vacunacion en dosis unica con mycoplasma hyopneumoniae
ATE309821T1 (de) Influenzavirus-impfstoffzusammensetzung
ATE526411T1 (de) Avirulente, immunogene flavivirus-chimäre
Thiry et al. Recombination in the alphaherpesvirus bovine herpesvirus 1
FI3244920T3 (fi) Suu- ja sorkkatautirokote
BR0207988A (pt) Cepas atenuadas vivas de vìrus de prrs
DK1425404T3 (da) Vaccinia-MVA-E3L-mutanter og anvendelse deraf
AR031599A1 (es) Vacunas para el virus herpes equino tipo 1: virus que hospeda mutaciones dentro del gen inmediato precoz
CY1106570T1 (el) Σταθερες, εξασθενημενες μεταλλαγμενες μορφες ιου λυσσας και ζωντανια εμβολια αυτων
AR019250A1 (es) Formas atenuadas del virus de la diarrea viral bovina, molecula de acido nucleico, vector, uso, metodo para modificar el genoma viral de tipo salvaje, genoma modificado, vacuna, metodo para atenuar un virus bvd de tipo salvaje
ES2141093T3 (es) Herpesvirus equinos (ehv) que contienen adn ajeno, procedimiento para su obtencion y su empleo en vacunas.
AR040623A1 (es) Vacuna contra el virus de la aftosa.
ES2120989T3 (es) Vector virico recombinante de tipo varicela-zoster.
US20200138937A1 (en) Genetically Attenuated Nucleic Acid Vaccine
ES2132330T3 (es) Vacuna para la proteccion de caballos frente a la infeccion por el virus del herpes equino.
PE20001331A1 (es) Identificacion de genotipos senv

Legal Events

Date Code Title Description
FA Abandonment or withdrawal